{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T12:21:31Z","timestamp":1753359691413,"version":"3.40.3"},"reference-count":20,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2023,10,18]]},"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1136\/ejhpharm-2022-003511","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T18:20:32Z","timestamp":1699467632000},"page":"190-192","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical experience with immunotherapy in patients with diffuse intrinsic pontine glioma"],"prefix":"10.1136","volume":"32","clinical-trial-number":[{"clinical-trial-number":"nct03178032","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0789-8998","authenticated-orcid":false,"given":"M\u00f3nica","family":"Gasanz Garicochea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Mart\u00ednez-Romera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2169-9266","authenticated-orcid":false,"given":"Marta Pilar","family":"Osuna-Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"L\u00f3pez-Ibor Ali\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"2025032704500669000_32.2.190.1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/13543784.2016.1182497","article-title":"Investigational New Drugs for Brain Cancer","volume":"25","author":"Staedtke","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"2025032704500669000_32.2.190.2","first-page":"1041","article-title":"Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: from bench to clinic and vice versa (review)","volume":"52","author":"Scutti","year":"2018","journal-title":"Int J Oncol"},{"key":"2025032704500669000_32.2.190.3","doi-asserted-by":"crossref","DOI":"10.1007\/s11940-019-0577-y","article-title":"Diffuse intrinsic pontine glioma: from diagnosis to next-generation clinical trials","volume":"21","author":"Vitanza","year":"2019","journal-title":"Curr Treat Options Neurol"},{"key":"2025032704500669000_32.2.190.4","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now101"},{"key":"2025032704500669000_32.2.190.5","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2018.1425617"},{"key":"2025032704500669000_32.2.190.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2214-0"},{"key":"2025032704500669000_32.2.190.7","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2217\/cns.14.47","article-title":"Management of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis","volume":"3","author":"Kaye","year":"2014","journal-title":"CNS Oncol"},{"key":"2025032704500669000_32.2.190.8","doi-asserted-by":"crossref","first-page":"13930","DOI":"10.1038\/s41598-018-32353-x","article-title":"Enhanced sensitivity of patient-derived pediatric high-grade brain tumor Xenografts to Oncolytic HSV-1 Virotherapy correlates with Nectin-1 expression","volume":"8","author":"Friedman","year":"2018","journal-title":"Sci Rep"},{"key":"2025032704500669000_32.2.190.9","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/13543784.2019.1694000","article-title":"DNX-2401: an investigational drug for the treatment of recurrent glioblastoma","volume":"28","author":"Philbrick","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"2025032704500669000_32.2.190.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202028"},{"key":"2025032704500669000_32.2.190.11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.phoj.2020.06.014","article-title":"Oncolytic viral therapy with anti PD-1 Immunotherapy in a pediatric patient with diffuse intrinsic pontine glioma","volume":"5","author":"Osuna Marco","year":"2020","journal-title":"Pediatric Hematology Oncology Journal"},{"key":"2025032704500669000_32.2.190.12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7577","article-title":"Intravenous delivery of Oncolytic Reovirus to brain tumor patients Immunologically primes for subsequent Checkpoint blockade","volume":"10","author":"Samson","year":"2018","journal-title":"Sci Transl Med"},{"key":"2025032704500669000_32.2.190.13","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab155"},{"key":"2025032704500669000_32.2.190.14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-017-0455-6","article-title":"Blocking the PD-1\/PD-L1 pathway in glioma: a potential new treatment strategy","volume":"10","author":"Xue","year":"2017","journal-title":"J Hematol Oncol"},{"key":"2025032704500669000_32.2.190.15","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/neuonc\/noac117","article-title":"The intrinsic and Microenvironmental features of diffuse midline glioma: implications for the development of effective Immunotherapeutic treatment strategies","volume":"24","author":"Persson","year":"2022","journal-title":"Neuro Oncol"},{"key":"2025032704500669000_32.2.190.16","doi-asserted-by":"crossref","first-page":"937253","DOI":"10.1155\/2012\/937253","article-title":"Modulation of tumor tolerance in primary central nervous system malignancies","volume":"2012","author":"Johnson","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"2025032704500669000_32.2.190.17","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2124058","article-title":"Immunotherapy approaches for the treatment of diffuse midline gliomas","volume":"11","author":"Bernstock","year":"2022","journal-title":"Oncoimmunology"},{"key":"2025032704500669000_32.2.190.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.8219"},{"key":"2025032704500669000_32.2.190.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.6552"},{"key":"2025032704500669000_32.2.190.20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2900"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2022-003511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T11:52:25Z","timestamp":1743076345000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2022-003511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,21]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/ejhpharm-2022-003511"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2022-003511","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"type":"print","value":"2047-9956"},{"type":"electronic","value":"2047-9964"}],"subject":[],"published":{"date-parts":[[2023,11,8]]}}}